Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate...

|About: Nektar Therapeutics (NKTR)|By:, SA News Editor

Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate NKTR-192, a short-acting mu-opioid analgesic for the treatment of acute pain, achieved its target pharmacokinetic profile. The company also says that dosing has commenced in a second Phase 1a clinical study which will explore the pharmacodynamic profile of the drug in healthy subjects.